Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for prevention of postoperative pulmonary complications
ISRCTN15109717Phase 3Active, not recruiting
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Feb 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, open-label trial of Sugammadex, neostigmine and glycopyrronium in postoperative respiratory complications (PRC) (2 arms), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Days alive and out of hospital at 30 days following surgery. Started Feb 2023; status: active, not recruiting.
02
Drugs
Sugammadexneostigmineglycopyrronium
03
Conditions
postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ISRCTN15109717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15109717.